



**EAACI**  
EUROPEAN ACADEMY OF ALLERGY  
AND CLINICAL IMMUNOLOGY

# ***EAACI Pediatric Section***

***Summary of activities***  
***July 2020***

# EAACI Pediatric Section report



*Dear Members,*

*We hope this email finds you well in these challenging times.*

*We present herein the activities of the EAACI Pediatric Board, including ongoing and completed task forces, publications, collaborations, outreach and meetings.*

*We also include reports from:*

- 1) Pediatric Allergy and Immunology journal ([here](#))*
- 2) European Training Committee in Pediatric Allergology ([here](#))*
- 3) Clement von Pirquet Foundation ([here](#)).*

*Warm regards,*

*The EAACI Pediatric Section Board*

**Chair**

Helen Brough  
MD PhD



**Secretary**

Stefania Arasi  
MD PhD



**Past Chair**

Montserrat Alvaro  
Lozano



Marta Vazquez-Ortiz  
MD PhD




Pablo Rodríguez del  
Río  
MD PhD




Elena Galli  
MD PhD



Sophia Tsabouri  
MD PhD



Daniel Munblit  
MD PhD



Burcin Beken  
MD - JMA





# Pediatric Section Mission Statement

Engaging patients, colleagues, members of the Pediatric Section, other EAACI Sections/IG/WG, national societies and patient organisations

*Current number of members: 3242*

Junior Members: 1234

from 107 countries worldwide

# Education Achievements in 2018-2020



Chair: Montserrat Alvaro Lozano  
Secretary: Carmen Riggioni  
Collaboration: Pediatric, Immunotherapy, Food allergy, JMA

Participation in all scientific programme committee meetings and marathon meetings



Section participation in formulating and submitting exam questions for the Pediatric arm of the EAACI UEMS exam



**PAAM 2019**  
17 - 19 October 2019  
Florence, Italy  
www.eaaci.org/paam2019



Chair: Montserrat Alvaro Lozano  
Co-Chair and Local-Chair: Antonella Muraro



REVIEW

WILEY



# Preventing food allergy in infancy and childhood: Systematic review of randomised controlled trials


Debra de Silva<sup>1</sup>  | Susanne Halcken<sup>2</sup>  | Chris Singh<sup>1</sup> | Antonella Muraro<sup>3</sup>  |  
Elizabeth Angier<sup>4</sup> | Stefania Arasi<sup>5</sup>  | Hasan Arshad<sup>6,7,8</sup> | Kirsten Beyer<sup>9</sup> |  
Robert Boyle<sup>10</sup> | George du Toit<sup>11</sup> | Philippe Eigenmann<sup>12</sup>  | Kate Grimshaw<sup>7,13</sup> |  
Arne Hoest<sup>2</sup> | Carla Jones<sup>14</sup> | Ekaterina Khaleva<sup>15</sup>  | Gideon Lack<sup>11</sup> |  
Hania Szajewska<sup>16</sup>  | Carina Venter<sup>17</sup>  | Valérie Verhasselt<sup>18</sup> |  
Graham Roberts<sup>6,8,15</sup>  | on behalf of European Academy of Allergy,  
Clinical Immunology Food Allergy, Anaphylaxis Guidelines Group

→ Food Allergy Prevention Guidelines – consultation process ongoing





> Allergy. 2020 Jun 19. doi: 10.1111/all.14459. Online ahead of print.

# EAACI Guideline on the Effective Transition of Adolescents and Young Adults With Allergy and Asthma

Graham Roberts<sup>1 2 3</sup>, Marta Vazquez-Ortiz<sup>4</sup>, Rebecca Knibb<sup>5</sup>, Ekaterina Khaleva<sup>1</sup>, Cherry Alviani<sup>1 3</sup>, Elizabeth Angier<sup>6</sup>, Katharina Blumchen<sup>7</sup>, Pasquale Comberiati<sup>8 9</sup>, Bettina Duca<sup>4 10</sup>, Audrey DunnGalvin<sup>11 12</sup>, Teresa Garriga-Baraut<sup>13</sup>, Claudia Gore<sup>4 10</sup>, M Hazel Gowland<sup>14</sup>, Valérie Hox<sup>15</sup>, Britt Jensen<sup>16</sup>, Charlotte G Mortz<sup>16</sup>, Oliver Pfaar<sup>17</sup>, Helena Pite<sup>18</sup>, Alexandra F Santos<sup>19 20 21</sup>, Silvia Sanchez-Garcia<sup>22</sup>, Frans Timmermans<sup>23</sup>



# Diagnosis and management of Non-IgE gastrointestinal allergies in breastfed infants—An EAACI Position Paper

Rosan Meyer<sup>1</sup>  | Adriana Chebar Lozinsky<sup>2</sup> | David M. Fleischer<sup>3</sup> |  
Mario C. Vieira<sup>4</sup> | George Du Toit<sup>5</sup> | Yvan Vandenplas<sup>6</sup> | Christophe Dupont<sup>7</sup> |  
Rebecca Knibb<sup>8</sup>  | Pinar Uysal<sup>9</sup> | Ozlem Cavkaytar<sup>10</sup> | Anna Nowak-Wegrzyn<sup>11</sup>  |  
Neil Shah<sup>12</sup> | Carina Venter<sup>3</sup> 

ENIGMA Task force collaboration with Allied Health IG and Food Allergy IG









# COVID – 19


Scientific contribution  
from the Pediatric Section Board  
inside EAACI activities

REVIEW

# Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics

Helen A. Brough<sup>1</sup>  | Omer Kalayci<sup>2</sup>  | Anna Sediva<sup>3</sup> | Eva Untersmayr<sup>4</sup> | Daniel Munblit<sup>5,6</sup> | Pablo Rodriguez del Rio<sup>7</sup> | Marta Vazquez-Ortiz<sup>6</sup>  | Stefania Arasi<sup>8</sup>  | Montserrat Alvaro-Lozano<sup>9</sup> | Sophia Tsabouri<sup>10</sup> | Elena Galli<sup>11</sup> | Burcin Beken<sup>12</sup>  | Philippe A. Eigenmann<sup>13</sup> 


Pediatr Allergy Immunol. 2020 Apr 22;10.1111/pai.13262. doi: 10.1111/pai.13262.



> Allergy. 2020 Jun 12. doi: 10.1111/all.14453. Online ahead of print.

# COVID-19 Pandemic: Practical Considerations on the Organization of an Allergy Clinic – An EAACI/ARIA Position Paper


O Pfaar<sup>1</sup>, L Klimek<sup>2</sup>, M Jutel<sup>3</sup>, C A Akdis<sup>4</sup>, J Bousquet<sup>5 6 7</sup>, H Breiteneder<sup>8</sup>, S Chinthrajah<sup>9</sup>, Z Diamant<sup>10 11 12</sup>, T Eiwegger<sup>13 14 15</sup>, W J Fokkens<sup>16</sup>, H W Fritsch<sup>17</sup>, K C Nadeau<sup>9</sup>, R E O'Hehir<sup>18 19</sup>, L O'Mahony<sup>20</sup>, W Rief<sup>21</sup>, V Sampath<sup>9</sup>, M Schedlowski<sup>22</sup>, M Torres<sup>23</sup>, C Traidl-Hoffmann<sup>24 25</sup>, D Y Wang<sup>26</sup>, L Zhang<sup>27</sup>, M Bonini<sup>28 29</sup>, R Brehler<sup>30</sup>, H A Brough<sup>31 32</sup>, T Chivato<sup>33</sup>, S Del Giacco<sup>34</sup>, S Dramburg<sup>35</sup>, R Gawlik<sup>36</sup>, A Gelincik<sup>37</sup>, K Hoffmann-Sommergruber<sup>8</sup>, V Hox<sup>38</sup>, E Knol<sup>39</sup>, A Lauerma<sup>40</sup>, P M Matricardi<sup>35</sup>, C G Mortz<sup>41</sup>, M Ollert<sup>41 42</sup>, O Palomares<sup>43</sup>, C Riggioni<sup>44 45</sup>, J Schwarze<sup>46</sup>, I Skypala<sup>28 47</sup>, S Untersmayr<sup>8</sup>, J Walusiak-Skorupa<sup>48</sup>, I Ansotegui<sup>49</sup>, C Bachert<sup>50 51 52</sup>, A Bedbrook<sup>7</sup>, S Bosnic-Anticevich<sup>53</sup>, L Brussino<sup>54</sup>, G W Canonica<sup>55</sup>, V Cardona<sup>56</sup>, P Carreiro-Martins<sup>57 58</sup>, A A Cruz<sup>59</sup>, W Czarlewski<sup>7 60</sup>, J A Fonseca<sup>61</sup>, M Gotua<sup>62</sup>, T Haatela<sup>63</sup>, J C Ivancevich<sup>64</sup>, P Kuna<sup>65</sup>, V Kvedariene<sup>66 67</sup>, D Larenas-Linnemann<sup>68</sup>, A Latiff<sup>69</sup>, M Morais-Almeida<sup>70</sup>, J Mullol<sup>71</sup>, R Naclerio<sup>72</sup>, K Ohta<sup>73</sup>, Y Okamoto<sup>74</sup>, G L Onorato<sup>7</sup>, N G Papadopoulos<sup>75 76</sup>, V Patella<sup>77</sup>, F S Regateiro<sup>78</sup>, B Samolinski<sup>79</sup>, C Suppli Ulrik<sup>80</sup>, S Toppila-Salmi<sup>81</sup>, A Valiulis<sup>82</sup>, M T Ventura<sup>83</sup>, A Yorgancioglu<sup>84</sup>, T Zuberbier<sup>85</sup>, I Agache<sup>86 87</sup>



➤ [Allergy](#). 2020 Apr 19. doi: 10.1111/all.14329. Online ahead of print.

# In-vivo Diagnostic Test Allergens in Europe: A Call to Action and Proposal for Recovery Plan – An EAACI Position Paper

L Klimek<sup>1</sup>, H J Hoffmann<sup>2</sup>, A F Kalpaklioglu<sup>3</sup>, P Demoly<sup>4</sup>, L Agache<sup>5</sup>, T Popov<sup>6</sup>, A Muraro<sup>7</sup>, P Schmid-Grendelmeier<sup>8</sup>, S Bonini<sup>9</sup>, A Bonertz<sup>10</sup>, V Mahler<sup>10</sup>, S Vieths<sup>10</sup>, O Pfaar<sup>11</sup>, T Zuberbier<sup>12</sup>, M Jutel<sup>13</sup>, C Schmidt-Weber<sup>14</sup>, P Hellings<sup>15</sup>, S Dreborg<sup>16</sup>, M Bonini<sup>17</sup><sup>18</sup>, H A Brough<sup>19</sup>, J Bousquet<sup>20</sup>, K Hoffmann-Sommergruber<sup>21</sup>, O Palomares<sup>22</sup>, M Ollert<sup>23</sup>, M H Shamji<sup>24</sup>, V Cardona<sup>25</sup>





**EAACI**  
EUROPEAN ACADEMY OF ALLERGY  
AND CLINICAL IMMUNOLOGY

[MEMBERS LOGIN](#) | [BECOME A MEMBER](#) | [CONTACT US](#) | [JOB CENTER](#) | [FOR PATIENTS](#) | ⋮

[EAACI](#) [EVENTS](#) [SCIENCE](#) [EDUCATION](#) [ADVOCACY](#) [MEDIA](#)



# EAACI resource centre COVID-19




## COVID-19 Resource Centre

Starting from December 2019, a new strain of human coronavirus was detected, initially called 2019-nCoV, in few patients with viral pneumonia in Wuhan, China. Although a specific treatment is currently still unavailable, physicians have several options to help patients by managing symptoms with drugs and supportive systems. The EAACI community is united in disseminating new research and knowledge on COVID-19. Find some of the most useful related content here, to better serve you and your patients. More resources on COVID-19 will be added as they are released by our community of experts.

Initiative led by Wojech Feleszko  
Food Allergy Chair: Stefania Arasi  
Co-Chair: Alberto Alvarez-Perea

# EAACI Explains Vaccination




<https://patients.eaaci.org/>

Initiative led by the Immunology Section

Chairs: Eva Untermeyer and Milena Solokowska

Contributors from the Pediatric Section Board:  
Helen Brough, Montserrat Alvaro-Lozano and Stefania Arasi



*Top Reviewer Certificate*

**Stefania Arasi**



# Clement von Pirquet Foundation Fellowship


Food allergy and gastrointestinal disease

## Association of *Staphylococcus aureus* colonization with food allergy occurs independently of eczema severity

Check for updates

Olympia Tsilochristou, MD,<sup>a,b</sup> George du Toit, MB, BCh, FRCPCH,<sup>a,b,c</sup> Peter H. Sayre, MD, PhD,<sup>d</sup> Graham Roberts, FRCPCH, DM,<sup>e,f</sup> Kaitie Lawson, MS,<sup>g</sup> Michelle L. Sever, MSPH, PhD,<sup>g</sup> Henry T. Bahnson, MPH,<sup>h</sup> Suzana Radulovic, MD,<sup>a,b,c</sup> Monica Basting, MA,<sup>a,b,c</sup> Marshall Plaut, MD,<sup>i</sup> and Gideon Lack, MB, BCh, FRCPCH,<sup>a,b,c</sup> for the Immune Tolerance Network Learning Early About Peanut Allergy Study Team *London, Southampton, and Isle of Wight, United Kingdom; San Francisco, Calif; Chapel Hill, NC; and Bethesda, Md*

### GRAPHICAL ABSTRACT



J Allergy Clin Immunol 2019; 144:494-503

## EAACI Annual Congress 2019

*S. aureus* an important risk factor contributing to food allergy in children with atopic dermatitis



*S. aureus* could be an important risk factor contributing to food allergy in children with atopic dermatitis, according to the newly released study results that Professor George du Toit presented on 2 June at the EAACI Annual Congress in Lisbon, during the Presidential Symposium on Immunomodulation in Food Allergy (Practall 2018). These results were published two days earlier in the Journal of Allergy and Clinical Immunology and were presented for the first time during the Congress Session.

*"We yet do not know the exact mechanisms that lead from atopic dermatitis to food allergy. However, our results suggest that Staphylococcus aureus could be an important factor contributing to this outcome"*

said Dr Olympia Tsilochristou, King's College London, the leading author of the paper. This study presents results from an exploratory secondary analysis of data from the groundbreaking Learning Early About Peanut Allergy (LEAP) study which Professor Gideon Lack has been leading at King's College London. The authors demonstrated that children with severe atopic dermatitis (AD) and/or egg allergy who had skin colonisation with *S. aureus* had higher sIgE values against peanut and egg white as opposed to those who were never colonised with *S. aureus*. Of note, these results were independent of AD severity.

Additionally, it was shown that children with skin and/or nasal *S. aureus* colonisation were more likely to have their egg allergy persist until the age of 5

*"The role of S. aureus should be considered in future studies aimed at inducing and maintaining tolerance to food allergens in infants with AD"*

said Professor du Toit, co-author of the paper and leading author of previous LEAP publications, while Professor Lack concluded by highlighting that

*"Further prospective longitudinal studies measuring S. aureus with more advanced techniques and interventional studies eradicating S. aureus in early infancy will help elucidate its role in the development of AD or food allergy"*

These study results are important as the analysis was made by correcting for AD severity. Previous findings in the literature that *S. aureus* colonisation in AD is associated with food sensitisation and allergy may have been confounded by AD severity. *S. aureus* has been implicated in the development and severity of atopic diseases namely AD, allergic rhinitis and asthma and the findings presented today extend these observations to the development of food allergy, independent of AD severity.

EAACI would like to take the opportunity to highlight the dynamics the new generation of allergists within its membership. Olympia Tsilochristou, based at King's College London, has been an active Junior Member of the Academy and was once awarded an EAACI Clinical Fellowship.



# Task forces table of Content

- 1** Food immunotherapy practice in Europe (FIND project)
- 2** Allergic diseases in adolescents and young people
- 3** Clinical outcomes of efficacy in food allergen immunotherapy trials
- 4** Targeting the skin barrier in atopic dermatitis
- 5** Chronic urticaria in children
- 6** Perceptions, Beliefs, Attitudes, and Decision making in parents of children with allergic diseases (PARANOID)
- 7** Public Outreach: scoping the needs and developing video resources for the public

# 1 Food immunotherapy practice in Europe (FIND project)

## Objectives

.- Mapping the number and characteristics of centers performing food AIT across Europe

## Current situation

.- Data collection and analysis phase finished. Manuscript on preparation

## Potential finishing date

.- End 2020

## Deliverables

.- Manuscript in an EAACI journal



# 2

## TF on Adolescents and Young Adults (AYA) with allergy and asthma



### Objectives

To provide a framework on the particular features of AYA with allergic diseases, their challenges and specific needs, as well as on strategies proven effective to improve their self-care and wellbeing. This will allow produce specific recommendations to optimize healthcare and outcomes in this critical age group, as well as to identify unmet needs and further work required in the field.

### Deliverables/Output

#### Published scientific papers:

- Knibb RC, et al. The effectiveness of interventions to improve self-management for adolescents and young adults with allergic conditions: a systematic review. *Allergy*. 2020. PMID: 32159856
- Khaleva E, et al. Current transition management of adolescents and young adults with allergy and asthma: A European survey. *Clinical Traslational Allergy* 2020 (in press).
- Roberts G, et al. EAACI guideline on the effective transition of adolescents and young adults with allergy and asthma. *Allergy*. 2020
- Vazquez-Ortiz M, et al. Understanding the challenges faced by adolescents and young adults with allergic conditions: a systematic review. *Allergy*. 2020. PMID: 32141620

#### Upcoming papers:

- Parents and AYA perspectives on practice recommendations for transitional care in allergy
- 'The teen toolkit' EAACI position paper on how to implement effective transitional care in allergy in clinical practice

#### Dissemination/Training:

- Short videos on TF output, EAACI Autumn 2019 and Spring 2020 Newsletters, Symposia at FAAM 2018, EAACI 2019 and 2020, PAAM 2019.
- Masterclass on Adolescents and Young Adults – 2021, Geneva
- Elearning module on Adolescents and Young Adults – late 2021

**Estimated TF completion: 2021**

# 3

## Clinical outcomes of efficacy in food allergen immunotherapy trials

### Objectives

.- Literature review on clinical efficacy outcomes used so far, assessment of the impact of using different definitions of efficacy and different statistical methods for analysis, gather information on the patient's perspective on efficacy outcomes

### Current situation


.- Partial completion of all work packages

### Potential finishing date

.- For the literature results first Q 2021, for the evaluation on efficacy definitions end of 2021 and for the patient's perception on the treatment 2022

### Deliverables

.- Most probably 1 manuscript per objective



# 4

## Targeting the skin barrier in atopic dermatitis

### **Objectives**

.- To provide evidence on whether the daily use of topical moisturizers or emollients soon after birth and for the first months of life could reduce the occurrence of atopic dermatitis and/or its severity, thus representing a low cost, easy to apply, safe and effective approach for the primary prevention of such disease

### **Current situation**

.- Currently reviewing published randomized clinical trials

### **Potential finishing date**

.- December 2020

### **Deliverables**

.- Manuscript publication

# 5 Chronic urticaria in children

## Objectives

- determine present clinical practice and challenges that arise from diagnosing and treating children with CU
- form a collaborative network to review and optimise diagnosis and treatment of children with CU via working groups

## Current situation

- A clinical survey of 35 questions has been disseminated to all the EAACI members of the pediatric section and was answered by 358 participants from 69 countries
- The first results have been analysed and presented to the digital EAACI 2020

## Potential finishing date

- at the end of 2020

## Deliverables

- A survey report summarizing current referral and management practices for chronic urticaria and angioedema in children across Europe
- To address questions on the use of omalizumab in the treatment of children with CU
- The establishment of a multi-centred international network for CU in children, with maximal inclusion of those who manage the condition in children, from EAACI's member countries

# 6

## Perceptions, Beliefs, Attitudes, and Decision making in parents of children with allergic diseases (PARANOID)

### Objectives

- Assess worries and beliefs, anxiety, allergic diseases perception, medical trust/mistrust and compliance among the parents of allergic children residing in different European countries
- Study factors impacting above mentioned outcomes with a particular focus on internet social networks

### Current situation

Survey questionnaire development

### Potential finishing date

June 2021

### Deliverables

Position paper on pan-European perceptions, beliefs and attitudes in parents of allergic children

# 7

## Public Outreach: scoping the needs and developing video resources for the public

### Objectives

- To improve awareness of what patients and the public want to know
- To obtain qualitative and quantitative assessment of the value of interactive models during the clinical village
- The development of educational material for the online media library and patient portal

### Current situation

Interactive models development

### Potential finishing date

December 2021

### Deliverables

Educational videos for future use in EAACI public outreach programmes, EAACI meetings, the EAACI online media library and patient portal



# Collaboration with other Sections/IG/WG

Task force title	Chair/Secretary	Section/ IG
Creating a video about immunotherapy for the public using the EAACI Clinical Village	Montserrat Alvaro Lozano Mohamed Shamji	Immunotherapy IG
Guidelines for Food Allergy and Anaphylaxis <ul style="list-style-type: none"> <li>Prevention of Food Allergy 2020 Guideline</li> <li>Anaphylaxis Guideline</li> </ul>	Antonella Muraro, Graham Roberts  Susanne Halcken, Antonella Muraro , Graham Roberts  Antonella Muraro, Margitta Worm and Graham Roberts	Food Allergy and Anaphylaxis Guidelines Group
Eustachian tube dysfunction: the role of immunity and allergy	Ludger Klimek Helen Brough	ENT Section
Immunological outcome measures for AIT in children and adults	Mohamed Shamji Montserrat Alvaro Lozano	Immunotherapy IG
Public outreach: lay summaries for EAACI position papers	Rodrigo Jimenez-Said Henry McSorley	Immunology
Food allergy in children with atopic dermatitis: an algorithm for diagnosis and risk evaluation	Charlotte Mortz Barbara Ballmer-Weber	Dermatology
Expert review on Allergen immunotherapy and Prevention of allergy in children.	Umit Sahiner	Immunotherapy IG

# Engagement with patients

## Mental Health Needs and Access to Care among Patients with Food Allergy

Collaborative project with EAACI Patient Organisation Committee

- Assess food allergy patients' psychosocial needs and access to mental health care in Europe, Australia, Canada.
- Compare findings from these countries to the findings from the United States.
- To improve food allergy patient outcomes by ensuring that patients' psychosocial needs are met.
- Successful grant application to Novartis
- Questionnaires designed and undergoing translations

# Patient advocacy work (1)



- 1. Advocating against discrimination of people with food allergy, with a special focus on vulnerable groups (e.g. children)
- 2. Identifying the unmet needs and raising awareness on the quality of life of people with food allergies and on the burden of the disease among policy makers
- 3. Improving the management of food allergens by food business operators and restaurants

# Patient advocacy work (2)



- The 'Food DETECTives' report was presented to Members of the European Parliament in Brussels in Dec 2019
  - [https://www.efanet.org/images/2019/FD\\_FINAL.pdf](https://www.efanet.org/images/2019/FD_FINAL.pdf)
- Outlines legislative gaps in food labelling for food allergic patients and recommendations for policymakers, public health authorities and the food industry.



*Thank you  
for your active collaboration  
and continuous support*